Weiheng Hu

449 total citations
35 papers, 334 citations indexed

About

Weiheng Hu is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Epidemiology. According to data from OpenAlex, Weiheng Hu has authored 35 papers receiving a total of 334 indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Oncology, 20 papers in Pulmonary and Respiratory Medicine and 8 papers in Epidemiology. Recurrent topics in Weiheng Hu's work include Lung Cancer Treatments and Mutations (17 papers), Lung Cancer Research Studies (11 papers) and Lung Cancer Diagnosis and Treatment (9 papers). Weiheng Hu is often cited by papers focused on Lung Cancer Treatments and Mutations (17 papers), Lung Cancer Research Studies (11 papers) and Lung Cancer Diagnosis and Treatment (9 papers). Weiheng Hu collaborates with scholars based in China, Ethiopia and Taiwan. Weiheng Hu's co-authors include Guangming Tian, Jun Nie, Xiangjuan Ma, Jindi Han, Di Wu, Ling Dai, Xiaoling Chen, Sen Han, Ziran Zhang and Jie Zhang and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Medicine & Science in Sports & Exercise.

In The Last Decade

Weiheng Hu

31 papers receiving 327 citations

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Weiheng Hu 268 154 59 59 52 35 334
Xiangjuan Ma 274 1.0× 153 1.0× 62 1.1× 69 1.2× 53 1.0× 34 335
Guangming Tian 291 1.1× 172 1.1× 63 1.1× 60 1.0× 54 1.0× 33 357
Ling Dai 238 0.9× 136 0.9× 105 1.8× 41 0.7× 53 1.0× 28 347
Ilze Bāra 260 1.0× 225 1.5× 57 1.0× 37 0.6× 40 0.8× 22 365
Moises J. Velez 234 0.9× 114 0.7× 85 1.4× 95 1.6× 40 0.8× 14 316
Ying Cheng 211 0.8× 102 0.7× 64 1.1× 59 1.0× 31 0.6× 48 269
Norimitsu Kasahara 196 0.7× 163 1.1× 40 0.7× 30 0.5× 26 0.5× 29 301
Linpeng Zheng 207 0.8× 150 1.0× 77 1.3× 32 0.5× 37 0.7× 17 304
M. Dómine Gómez 210 0.8× 128 0.8× 73 1.2× 37 0.6× 52 1.0× 36 277
Víctor Rodríguez-Freixinós 194 0.7× 129 0.8× 84 1.4× 61 1.0× 30 0.6× 27 319

Countries citing papers authored by Weiheng Hu

Since Specialization
Citations

This map shows the geographic impact of Weiheng Hu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Weiheng Hu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Weiheng Hu more than expected).

Fields of papers citing papers by Weiheng Hu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Weiheng Hu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Weiheng Hu. The network helps show where Weiheng Hu may publish in the future.

Co-authorship network of co-authors of Weiheng Hu

This figure shows the co-authorship network connecting the top 25 collaborators of Weiheng Hu. A scholar is included among the top collaborators of Weiheng Hu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Weiheng Hu. Weiheng Hu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Hu, Weiheng, et al.. (2025). Exercise Rescues Blood–Brain Barrier Structural Impairment and Enhances Mitochondrial Biogenesis in a Hypertensive Mouse Model. Medicine & Science in Sports & Exercise. 57(8). 1657–1668. 4 indexed citations
2.
Cao, Wenli, Sen Han, Lan Mi, et al.. (2025). Immune checkpoint inhibitor-related myocarditis in patients with lung cancer. BMC Cancer. 25(1). 685–685. 3 indexed citations
3.
Tian, Guangming, Jun Nie, Ling Dai, et al.. (2025). Real-world analysis of the efficacy and safety of lorlatinib in ALK-positive non-small cell lung cancer patients in China. Frontiers in Oncology. 15. 1577607–1577607.
4.
5.
Zhang, Jie, Liang Wang, Weiheng Hu, et al.. (2023). Aneuploid subtypes of circulating tumor cells and circulating tumor-derived endothelial cells predict the overall survival of advanced lung cancer. Frontiers in Oncology. 13. 829054–829054. 5 indexed citations
6.
Wang, Yang, Jun Nie, Ling Dai, et al.. (2023). Construction of an endoplasmic reticulum stress-related signature in lung adenocarcinoma by comprehensive bioinformatics analysis. BMC Pulmonary Medicine. 23(1). 172–172. 5 indexed citations
7.
Tian, Guangming, Xinliang Zhao, Jun Nie, et al.. (2022). The overall survival benefit in Chinese ALK+ NSCLC patients received targeted therapies. Journal of Thoracic Disease. 14(6). 2201–2212. 1 indexed citations
8.
Wang, Yang, Xuanye Zhang, Sen Han, et al.. (2022). Second‐line treatment options in advanced thymic carcinoma after failure of platinum‐based chemotherapy: A multicenter retrospective study. Cancer Medicine. 12(3). 2303–2311. 1 indexed citations
9.
10.
Wang, Yang, Jun Nie, Ling Dai, et al.. (2021). Evaluation of efficacy and toxicity of nivolumab combined with or without docetaxel in patients with advanced NSCLC. Cancer Immunology Immunotherapy. 71(2). 267–276. 4 indexed citations
11.
Chen, Xiaoling, Jun Nie, Ling Dai, et al.. (2021). Immune-Related Adverse Events and Their Association With the Effectiveness of PD-1/PD-L1 Inhibitors in Non-Small Cell Lung Cancer: A Real-World Study From China. Frontiers in Oncology. 11. 607531–607531. 28 indexed citations
12.
Ma, Xu, Jun Nie, Weiheng Hu, et al.. (2020). Diagnosis and Treatment Characteristics of Lung Cancer Patients with Venous Thromboembolism. SHILAP Revista de lepidopterología.
13.
Wu, Di, Jun Nie, Weiheng Hu, et al.. (2020). A phase II study of anlotinib in 45 patients with relapsed small cell lung cancer. International Journal of Cancer. 147(12). 3453–3460. 29 indexed citations
14.
Guo, Xiaojin, et al.. (2017). P2.01-011 The Efficiency and Safety of Apatinib plus S-1 as Second-Line or Laterline Chemotherapy for Advanced Squamous Cell Lung Carcinoma. Journal of Thoracic Oncology. 12(11). S2073–S2073. 4 indexed citations
15.
Hu, Weiheng, Jian Fang, Jun Nie, et al.. (2017). Efficacy and safety of endostar in the treatment of advanced lung squamous cell carcinoma.. Journal of Clinical Oncology. 35(15_suppl). e20574–e20574.
16.
Wu, Di, Jian Fang, Jun Nie, et al.. (2015). [Effects of Local Radiation Combined with Chemotherapy in the treatment of 
Patients with Extensive-stage Small Cell Lung Cancer].. SHILAP Revista de lepidopterología. 18(5). 272–9. 2 indexed citations
17.
Zhang, Jie, Jing Gao, Yanyan Li, et al.. (2015). Circulating PD‐L1 in NSCLC patients and the correlation between the level of PD‐L1 expression and the clinical characteristics. Thoracic Cancer. 6(4). 534–538. 109 indexed citations
18.
Zhang, Jie, Shaolei Li, Jindi Han, et al.. (2014). Retrospective study of surgery versus non‐surgical management in limited‐disease small cell lung cancer. Thoracic Cancer. 5(5). 405–410. 10 indexed citations
19.
Hu, Weiheng, Jian Fang, Jun Nie, et al.. (2014). Addition of aprepitant improves protection against cisplatin-induced emesis when a conventional anti-emetic regimen fails. Cancer Chemotherapy and Pharmacology. 73(6). 1129–1136. 4 indexed citations
20.
Shao, Yixue, Zhiwei Lin, Chong‐Jen Yu, et al.. (2009). Quality of life in advanced non-small cell lung cancer patients receiving first-line gefitinib monotherapy. Journal of Clinical Oncology. 27(15_suppl). 9614–9614. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Xiangjuan Ma Breakdown of academic impact, for papers by Guangming Tian Breakdown of academic impact, for papers by Ling Dai Breakdown of academic impact, for papers by Ilze Bāra Breakdown of academic impact, for papers by Moises J. Velez Breakdown of academic impact, for papers by Ying Cheng Breakdown of academic impact, for papers by Norimitsu Kasahara Breakdown of academic impact, for papers by Linpeng Zheng Breakdown of academic impact, for papers by M. Dómine Gómez Breakdown of academic impact, for papers by Víctor Rodríguez-Freixinós
Rankless by CCL
2026